NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis, Inc. is based in CARMEL, Ind.
| Revenue (Most Recent Fiscal Year) | $2.69M |
| Net Income (Most Recent Fiscal Year) | $-8.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 11.86 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -224.27% |
| Net Margin (Trailing 12 Months) | -230.61% |
| Return on Equity (Trailing 12 Months) | -350.51% |
| Return on Assets (Trailing 12 Months) | -150.16% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.59 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.55 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 6.65 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.98 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 10.65M |
| Free Float | 7.84M |
| Market Capitalization | $28.87M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 3.13 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 11.77% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |